Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites (Q42509440)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 November 2017

Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites (English)

1 reference

Europe PubMed Central

1 November 2017

Noritaka Nakamichi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Ken-Ichi Fujita

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yusuke Masuo

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Erina Yamazaki

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Toshiki Shibutani

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yutaro Kubota

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yasutsuna Sasaki

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yukio Kato

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

0 references

publication date

4 May 2017

1 reference

Europe PubMed Central

1 November 2017

Journal of Pharmaceutical Sciences

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

106

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

2632-2641

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Characterization of the transdermal transport of flurbiprofen and indomethacin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Characterization of ABC transporters in human skin

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

PDZK1 regulates breast cancer resistance protein in small intestine

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

International Transporter Consortium commentary on clinically important transporter polymorphisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.064

7 January 2021

Identifiers

10.1016/J.XPHS.2017.04.064

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28479358%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42509440&oldid=1960173029"